JP2000508351A - アミノフェノール誘導体およびその化粧品としての使用 - Google Patents
アミノフェノール誘導体およびその化粧品としての使用Info
- Publication number
- JP2000508351A JP2000508351A JP11514021A JP51402199A JP2000508351A JP 2000508351 A JP2000508351 A JP 2000508351A JP 11514021 A JP11514021 A JP 11514021A JP 51402199 A JP51402199 A JP 51402199A JP 2000508351 A JP2000508351 A JP 2000508351A
- Authority
- JP
- Japan
- Prior art keywords
- group
- unsaturated
- saturated
- hair
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 239000002537 cosmetic Substances 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 20
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 20
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 10
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 10
- 238000004061 bleaching Methods 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 4
- -1 anti-inflammatory Substances 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims description 9
- 102000003425 Tyrosinase Human genes 0.000 claims description 6
- 108060008724 Tyrosinase Proteins 0.000 claims description 6
- 239000007854 depigmenting agent Substances 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- SLPPBRLLAWJEIM-UHFFFAOYSA-N 1-ethyl-3-(4-hydroxyphenyl)urea Chemical compound CCNC(=O)NC1=CC=C(O)C=C1 SLPPBRLLAWJEIM-UHFFFAOYSA-N 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 239000007844 bleaching agent Substances 0.000 claims description 3
- 230000008099 melanin synthesis Effects 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 2
- 108010076876 Keratins Proteins 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims description 2
- BECNKUVYBNETOM-UHFFFAOYSA-N ethyl n-(4-hydroxyphenyl)carbamate Chemical group CCOC(=O)NC1=CC=C(O)C=C1 BECNKUVYBNETOM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000645 desinfectant Substances 0.000 claims 1
- NDMNOCFEDLHFKY-UHFFFAOYSA-N ethyl 5-(ethoxycarbonyloxyamino)-2-hydroxybenzoate Chemical compound C(C)OC(=O)ONC1=CC(=C(C=C1)O)C(=O)OCC NDMNOCFEDLHFKY-UHFFFAOYSA-N 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 230000003061 melanogenesis Effects 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 3
- 239000007957 coemulsifier Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000035614 depigmentation Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- NPVMUYGQDFCCHX-QRPNPIFTSA-N OC1=CC=CC=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 Chemical compound OC1=CC=CC=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 NPVMUYGQDFCCHX-QRPNPIFTSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 125000003901 ceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical class O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 125000002819 montanyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940032067 peg-20 stearate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/415—Aminophenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/08—Preparations for bleaching the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1./以下の式(I): (式中、Rは、水素原子または−COR2基を示し、 R2は、飽和または不飽和で、直鎖、環状または分岐の、任意にヒドロキシル 化した、C1−C30炭化水素またはアルコキシ基を示し、 R1は、以下の式(a)、(b)、または(c): (a) −CO−NR3R4 (b) −CO−O−R5 (c) −SO2−R5 の基であり、 R3は、水素原子、または、直鎖または分岐で飽和または不飽和の、任意にヒ ドロキシル化した、C1−C6炭化水素基を示し、 R4は、水素原子、または、飽和または不飽和で、直鎖、環状または分岐の、 任意にヒドロキシル化した、C1−C30炭化水素基を示し、 R5は、飽和または不飽和で、直鎖、環状または分岐の、任意にヒドロキシル 化した、C1−C30炭化水素基を示す) で表わされる、少なくとも1つのアミノフェノール誘導体を、ヒトの皮膚、体 毛、または頭髪用の、脱色素化および/またはブリーチ化粧品組成物中に使用す ることを特徴とする、アミノフェノール誘導体の使用。 2. 前記アミノフェノール誘導体が、以下の条件: −Rが水素原子である、 − フェニル基上の−OR官能基がオルトまたはパラ位にある、 − R1が式(a)または(b)の基である の少なくとも1つを満たすことを特徴とする請求項1に記載の使用。 3. 前記アミノフェノール誘導体が、N−エチルオキシカルボニル−4− アミノフェノール;N−エチルオキシカルボニル−O−エチルオキシカルボニル −4−アミノフェノール;N−コレステリルオキシカルボニル−4−アミノフェ ノール;またはN−エチルアミノカルボニル−4−アミノフェノールであること を特徴とする、請求項1または2に記載の使用。 4. 化粧品および/または皮膚用組成物中に、および/または、該組成物 の製造用に、チロシナーゼインヒビタとして、および/または、メラニン合成の インヒビタとして、請求項1ないし3のいずれかl項に定義した式(I)の少な くとも1つのアミノフェノール誘導体を使用することを特徴とする、アミノフェ ノール誘導体の使用。 5. 請求項1ないし4のいずれか1項に定義した式(I)の少なくとも1 つのアミノフェノール誘導体、および、化粧品としておよび/または皮膚科学的 に許容される媒体を含有する、化粧品および/または皮膚科学用組成物。 6. ヒトの皮膚を脱色素化および/またはブリーチするために、および/ または、皮膚から色素形成したマークを除去するために、および/または、体毛 および/または頭髪を脱色素化するために用いられる、請求項5に記載の組成物 。 7. アミノフェノール誘導体が、組成物の全重量の0.001から10% の量で、好ましくは0.005から5%の量で存在する、請求項5または6に記 載の組成物。 8. ケラチン溶解剤および/または上皮剥離剤、抗炎症剤、沈静剤、他の 脱色素化剤、およびこれらの混合物から選択される少なくとも1つの活性剤をさ らに含有する、請求項5ないし7のいずれか1項に記載の組成物。 R2は、飽和または不飽和で、直鎖、環状または分岐の、任意にヒドロキシル 化した、C1−C30炭化水素またはアルコキシ基を示し、 R1は、以下の式(a)、(b)、および(c): (a) −CO−NR3R4 (b) コレステリルオキシカルボニル基 (c) −SO2−R5 の基から選択され、 R3は、水素原子、または、直鎖または分岐で飽和または不飽和の、任意にヒ ドロキシル化した、C1−C6炭化水素基を示し、 R4は、飽和または不飽和で、直鎖、環状または分岐の、任意にヒドロキシル 化した、C13−C30炭化水素基を示し、 R5は、飽和または不飽和で、直鎖、環状または分岐の、任意にヒドロキシル 化した、C1−C30炭化水素基を示す) で表わされる、アミノフェノール誘導体。 10. 請求項5ないし8のいずれか1項で定義した組成物を、皮膚、体毛 、または頭髪に適用することを含む、ヒトの皮膚、体毛、または頭髪を脱色素化 および/またはブリーチするための美容処理方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/10710 | 1997-08-27 | ||
FR9710710A FR2767823B1 (fr) | 1997-08-27 | 1997-08-27 | Composes derives d'aminophenol et leur utilisation en cosmetique |
PCT/FR1998/001856 WO1999010318A1 (fr) | 1997-08-27 | 1998-08-26 | Derives d'aminophenol et leur utilisation en cosmetique |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000508351A true JP2000508351A (ja) | 2000-07-04 |
JP3514775B2 JP3514775B2 (ja) | 2004-03-31 |
Family
ID=9510539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51402199A Expired - Fee Related JP3514775B2 (ja) | 1997-08-27 | 1998-08-26 | アミノフェノール誘導体およびその化粧品としての使用 |
Country Status (14)
Country | Link |
---|---|
US (2) | US6423854B1 (ja) |
EP (1) | EP0966434B1 (ja) |
JP (1) | JP3514775B2 (ja) |
KR (1) | KR100308330B1 (ja) |
CN (1) | CN1079393C (ja) |
AR (1) | AR016645A1 (ja) |
AT (1) | ATE217862T1 (ja) |
BR (1) | BR9806236A (ja) |
CA (1) | CA2269897C (ja) |
DE (1) | DE69805515T2 (ja) |
ES (1) | ES2178250T3 (ja) |
FR (1) | FR2767823B1 (ja) |
TW (1) | TW460292B (ja) |
WO (1) | WO1999010318A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003113057A (ja) * | 2001-10-05 | 2003-04-18 | Shiseido Co Ltd | 脱色用固形組成物 |
JP2003113056A (ja) * | 2001-10-05 | 2003-04-18 | Shiseido Co Ltd | 脱色用固形組成物 |
WO2008047758A1 (fr) * | 2006-10-17 | 2008-04-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent anti-inflammatoire contenant du 2-aminophénol ou un dérivé de celui-ci en tant que principe actif |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448006A (en) | 1981-05-28 | 1984-05-15 | Donn Incorporated | Grid ceiling structure and method of converting |
FR2767823B1 (fr) * | 1997-08-27 | 1999-10-15 | Oreal | Composes derives d'aminophenol et leur utilisation en cosmetique |
FR2796838B1 (fr) * | 1999-07-26 | 2003-05-23 | Oreal | Composition a base de vesicules lamellaires lipidiques incorporant un derive d'amino-phenol, procede de preparation et utilisations |
FR2799645B1 (fr) * | 1999-10-13 | 2004-04-30 | Oreal | Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant |
FR2802416B1 (fr) * | 1999-12-20 | 2002-07-19 | Oreal | Composition cosmetique comprenant un derive d'aminophenol |
FR2802415B1 (fr) * | 1999-12-20 | 2002-07-19 | Oreal | Composition cosmetique comprenant le n-ethyloxycarbonyl-4- amino-phenol et l'arbutine ou ses derives et/ou l'acide ellagique ou ses derives |
FR2804866B1 (fr) * | 2000-02-16 | 2002-04-19 | Oreal | Composition a base n-cholesteryloxycarbonyl-4-para- aminophenol et d'hydroquinone ou l'un de ses derives |
FR2816502B1 (fr) * | 2000-11-10 | 2003-04-11 | Oreal | Composition cosmetique comprenant un derive d'aminophenol et un isoflavonoide |
FR2820320B1 (fr) * | 2001-02-02 | 2003-04-04 | Oreal | Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles |
FR2826275B1 (fr) * | 2001-06-26 | 2005-02-18 | Oreal | Composition notamment cosmetique contenant des derives d'aminophenol et des derives lipophiles d'acide amine |
EP1269986B1 (fr) * | 2001-06-26 | 2009-02-25 | L'oreal | Compositions comprenant un composé de faible solubilité et un dérivé lipophile d'acide aminé, utilisations et procédés correspondants |
FR2829696B1 (fr) | 2001-09-17 | 2004-02-27 | Oreal | Utilisation de l'acide pantetheine sulfonique et/ou de ses sels en tant qu'agent anti-radicalaire |
FR2825275A1 (fr) * | 2001-09-28 | 2002-12-06 | Oreal | Composition huileuse epaissie comprenant un derive d'aminophenol |
FR2830196A1 (fr) * | 2001-09-28 | 2003-04-04 | Oreal | Composition huileuse epaissie comprenant un derive d'aminophenol |
FR2871688B1 (fr) | 2004-06-16 | 2008-05-16 | Oreal | Procede pour favoriser la penetration d'un actif et composition permettant sa mise en oeuvre |
US8158136B2 (en) | 2004-08-18 | 2012-04-17 | L'oréal | Emulsification system for use in cosmetics |
US7300649B2 (en) | 2005-02-11 | 2007-11-27 | Genepharm, Inc. | Cosmetic and cosmeceutical compositions for restoration of skin barrier function |
FR2883168B1 (fr) | 2005-03-18 | 2008-01-11 | Oreal | Compositions cosmetiques de soin, renforcement et/ou reparation des substrats keratiniques comprenant des polypeptides kap |
FR2889808B1 (fr) | 2005-08-17 | 2011-07-22 | Oreal | Utilisation de l'acide 8-hexadecene-1,16-dicarboxylique comme agent de soin destine a favoriser la cohesion de la couche cornee |
FR2890557B1 (fr) * | 2005-09-14 | 2012-07-13 | Oreal | Composition cosmetique comprenant un actif et des particules contenant au moins un pigment inorganique colore dans une matrice, et utilisation en soin de peau. |
FR2894465B1 (fr) * | 2005-12-14 | 2010-09-10 | Fabre Pierre Dermo Cosmetique | Utilisation de composes polyinsatures en tant qu'agents blanchissants |
DE102006026038A1 (de) * | 2006-06-01 | 2007-12-06 | Henkel Kgaa | Aufhell- und/oder Färbemittel mit cyclischen Harnstoffderivaten |
FR2902999B1 (fr) | 2006-07-03 | 2012-09-28 | Oreal | Utilisation de derives c-glycoside a titre d'actif prodesquamant |
FR2918885B1 (fr) | 2007-07-17 | 2009-08-28 | Oreal | Utilisation d'extrait de bacterie cultivee sur eau thermale pour diminuer les poches et/ou les cernes perioculaires |
FR2931064B1 (fr) | 2008-05-14 | 2010-08-13 | Oreal | Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane |
FR2939309B1 (fr) | 2008-12-08 | 2010-12-17 | Oreal | Utilisation d'un derive ester de 2-pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant |
JP5819299B2 (ja) | 2009-11-20 | 2015-11-24 | ロレアル | 親油性有効成分を含む粘着性が低い化粧品用又は皮膚科用組成物 |
FR2953716B1 (fr) | 2009-12-16 | 2015-03-27 | Oreal | Kit de formulation d'un produit cosmetique |
FR2963233B1 (fr) | 2010-07-28 | 2014-03-14 | Oreal | Procede pour diminuer les hyperpigmentations post-reactionnelles |
WO2012105060A1 (en) | 2011-02-04 | 2012-08-09 | L'oreal | Composite pigment and method for preparation thereof |
FR2972346B1 (fr) | 2011-03-09 | 2013-11-08 | Oreal | Utilisation d'un derive diester d'acide 2-methyl succinique comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant |
WO2013010590A1 (en) | 2011-07-21 | 2013-01-24 | L'oreal | Cosmetic and/or dermatological composition containing a merocyanine derivative comprising specific polar groups consisting of hydroxyl- and ether-functionalities |
US9949897B2 (en) | 2012-04-11 | 2018-04-24 | L'oreal | Self-standing cosmetic sheet |
FR2992197B1 (fr) | 2012-06-21 | 2014-06-27 | Oreal | Composition cosmetique comprenant des particules diffusantes non interferentielles et des particules d'aerogel, et procede cosmetique d'eclaircissement |
FR2992173B1 (fr) | 2012-06-21 | 2014-10-24 | Oreal | Procece cosmetique d'eclaircissement de la peau et/ou des levres |
JP6100897B2 (ja) | 2012-07-13 | 2017-03-22 | ロレアル | 複合顔料及びその調製方法 |
US11266584B2 (en) | 2012-07-13 | 2022-03-08 | L'oreal | Cosmetic composition comprising composite sunscreen particles |
FR2996133B1 (fr) | 2012-10-02 | 2015-06-26 | Oreal | Nouvelles utilisations cosmetiques de polymeres dispersants en association avec au moins un actif |
FR3061002B1 (fr) | 2016-12-23 | 2019-05-24 | L'oreal | Composition comprenant de l’acide hydroxyethylpiperazine ethane sulfonique et au moins un alkylpolyglucoside |
FR3078891B1 (fr) | 2018-03-16 | 2020-12-25 | Centre Nat Rech Scient | Utilisation d’un extrait d’ilex aquifolium pour le traitement des desordres de la pigmentation et pour le blanchiment de la peau |
FR3100129A1 (fr) | 2019-08-26 | 2021-03-05 | Laboratoire Promicea | Nouvelle composition anti-taches d’hyperpigmentation |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2663730A (en) * | 1953-09-16 | 1953-12-22 | Ethyl Corp | N-alkyl-n'-(p-hydroxyphenyl) ureas |
DE1593520C3 (de) * | 1966-09-05 | 1974-07-11 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 3-(Carbamoyloxyphenyl)-harnstoffe bzw. -thioharnstoffe, diese enthaltende Mittel mit selektiver herbizider Wirkung sowie Verfahren zu deren Herstellung |
DE1949749C3 (de) * | 1969-10-02 | 1978-06-01 | Henkel & Kgaa, 4000 Duesseldorf | Mittel zum Färben menschlicher Haare |
DD107449A1 (ja) * | 1971-01-15 | 1974-08-05 | ||
US3933470A (en) * | 1972-06-30 | 1976-01-20 | American Cyanamid Company | Ester of (alkynyloxy)-, (alkenyloxy)-, and (cyanoalkoxy) carbanilic acids and their use as herbicides |
DE2323812A1 (de) * | 1973-05-11 | 1974-11-28 | Jenapharm Veb | Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe |
DE3510039A1 (de) * | 1985-03-20 | 1986-09-25 | Henkel KGaA, 4000 Düsseldorf | Haarfaerbemittel |
CA2035459A1 (en) * | 1989-07-25 | 1991-01-26 | Neil F. Haley | Method for treating skin to repair the effects of photoaging |
US5086060A (en) * | 1989-07-25 | 1992-02-04 | Eastman Kodak Company | Compound and method for treating skin for acne or psoriasis |
JPH06344672A (ja) * | 1993-06-04 | 1994-12-20 | Mitsubishi Paper Mills Ltd | 可逆性感熱記録材料およびその製造方法 |
JP3198214B2 (ja) * | 1994-02-15 | 2001-08-13 | 三菱製紙株式会社 | 可逆性感熱記録材料 |
CA2161376C (en) * | 1994-10-27 | 2005-01-11 | Toshiaki Minami | Reversible multi-color thermal recording medium |
JPH0977655A (ja) * | 1995-09-14 | 1997-03-25 | Mikimoto Pharmaceut Co Ltd | 皮膚外用剤 |
FR2756734B1 (fr) * | 1996-12-06 | 1999-01-15 | Oreal | Utilisation de paracetamol comme agent depigmentant |
FR2767823B1 (fr) * | 1997-08-27 | 1999-10-15 | Oreal | Composes derives d'aminophenol et leur utilisation en cosmetique |
-
1997
- 1997-08-27 FR FR9710710A patent/FR2767823B1/fr not_active Expired - Fee Related
-
1998
- 1998-08-26 DE DE69805515T patent/DE69805515T2/de not_active Expired - Lifetime
- 1998-08-26 CA CA002269897A patent/CA2269897C/fr not_active Expired - Fee Related
- 1998-08-26 CN CN98801244A patent/CN1079393C/zh not_active Expired - Fee Related
- 1998-08-26 US US09/284,490 patent/US6423854B1/en not_active Expired - Fee Related
- 1998-08-26 JP JP51402199A patent/JP3514775B2/ja not_active Expired - Fee Related
- 1998-08-26 EP EP98942789A patent/EP0966434B1/fr not_active Expired - Lifetime
- 1998-08-26 ES ES98942789T patent/ES2178250T3/es not_active Expired - Lifetime
- 1998-08-26 BR BR9806236A patent/BR9806236A/pt not_active Application Discontinuation
- 1998-08-26 AT AT98942789T patent/ATE217862T1/de not_active IP Right Cessation
- 1998-08-26 WO PCT/FR1998/001856 patent/WO1999010318A1/fr active IP Right Grant
- 1998-08-27 TW TW087114154A patent/TW460292B/zh not_active IP Right Cessation
- 1998-08-27 AR ARP980104263A patent/AR016645A1/es active IP Right Grant
-
1999
- 1999-04-26 KR KR1019997003638A patent/KR100308330B1/ko not_active IP Right Cessation
-
2002
- 2002-04-19 US US10/125,411 patent/US6924275B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003113057A (ja) * | 2001-10-05 | 2003-04-18 | Shiseido Co Ltd | 脱色用固形組成物 |
JP2003113056A (ja) * | 2001-10-05 | 2003-04-18 | Shiseido Co Ltd | 脱色用固形組成物 |
WO2008047758A1 (fr) * | 2006-10-17 | 2008-04-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent anti-inflammatoire contenant du 2-aminophénol ou un dérivé de celui-ci en tant que principe actif |
JP5357545B2 (ja) * | 2006-10-17 | 2013-12-04 | 株式会社林原 | 2−アミノフェノール又はその誘導体を有効成分とする抗炎症剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1237155A (zh) | 1999-12-01 |
US20020161040A1 (en) | 2002-10-31 |
US6924275B2 (en) | 2005-08-02 |
KR20000068837A (ko) | 2000-11-25 |
FR2767823A1 (fr) | 1999-03-05 |
ATE217862T1 (de) | 2002-06-15 |
AR016645A1 (es) | 2001-07-25 |
WO1999010318A1 (fr) | 1999-03-04 |
EP0966434B1 (fr) | 2002-05-22 |
DE69805515D1 (de) | 2002-06-27 |
CN1079393C (zh) | 2002-02-20 |
BR9806236A (pt) | 2000-03-21 |
ES2178250T3 (es) | 2002-12-16 |
US6423854B1 (en) | 2002-07-23 |
FR2767823B1 (fr) | 1999-10-15 |
DE69805515T2 (de) | 2002-11-21 |
CA2269897C (fr) | 2003-10-28 |
EP0966434A1 (fr) | 1999-12-29 |
TW460292B (en) | 2001-10-21 |
JP3514775B2 (ja) | 2004-03-31 |
KR100308330B1 (ko) | 2001-09-24 |
CA2269897A1 (fr) | 1999-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000508351A (ja) | アミノフェノール誘導体およびその化粧品としての使用 | |
US6365135B1 (en) | Use of amino phenol amide derivatives as depigmentation agents | |
JP3558653B2 (ja) | イミノフェノールフラグメントを有する少なくとも1つの化合物を含有する皮膚および/またはその表面成長体への局所適用用組成物 | |
US6306376B1 (en) | Use of arbutin monoesters as depigmenting agents | |
TW529956B (en) | Cosmetic and/or dermatological composition containing at least one extract of mulberry, at least one extract of skullcap and at least one salicylic acid derivative | |
US6326014B1 (en) | Use of oxamate derivatives as depigmenting agents | |
JP2005537332A (ja) | 新規ノルアポルフィン誘導体 | |
FR2751535A1 (fr) | Utilisation de derives de la melatonine pour la la depigmentation de la peau et compositions les comprenant | |
JPH05294821A (ja) | (2,5−ジヒドロキシフェニル)カルボン酸誘導体、それらの同族体又は塩を有効成分として含有する、脱色作用のある皮膚用又は化粧料組成物 | |
US7056498B2 (en) | Composition containing aminophenol derivative, use thereof, and process for dissolving aminophenol derivative | |
JP3001834B2 (ja) | N,n’−ジベンジルエチレンジアミン−n,n’−二酢酸誘導体からなる色素脱失剤 | |
US20070258921A1 (en) | Process for depigmenting the skin | |
JP3034486B2 (ja) | 新規なコウジ酸誘導体、並びに脱色素化剤としてのその用途 | |
US6228350B1 (en) | Method of depigmenting and/or bleaching skin and/or body hair or head hair | |
JP2873219B2 (ja) | 色素脱失剤としてオクトピロックスを含有する組成物およびその使用 | |
JP6957743B2 (ja) | 美容的使用のためのレゾルシノール誘導体 | |
US6960347B2 (en) | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | |
MXPA99003665A (en) | Aminophenol derivatives and their use in cosmetics | |
US20040161391A1 (en) | Ascorbic acid compounds as bleaching agents | |
JPH06321767A (ja) | 脱色作用を有する化粧料又は皮膚科用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040114 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080123 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090123 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090123 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100123 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110123 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110123 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120123 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130123 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130123 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |